Medicina
Departamento
Hospital Morales Meseguer
Murcia, EspañaPublicaciones en colaboración con investigadoras/es de Hospital Morales Meseguer (25)
2024
-
Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification
British Journal of Haematology, Vol. 204, Núm. 4, pp. 1529-1535
2023
-
Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes
HemaSphere, Vol. 7, Núm. 10, pp. E961
2022
-
Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial
Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661
-
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice
International Journal of Hematology, Vol. 116, Núm. 3, pp. 381-392
2020
-
Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain
Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 8, pp. 1534-1542
-
Recommendations of the Working Groups from the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC) for the management of adult critically ill patients in the coronavirus disease (COVID-19)
Medicina Intensiva, Vol. 44, Núm. 6, pp. 371-388
2019
-
High incidence of advanced colorectal neoplasia during endoscopic surveillance in serrated polyposis syndrome
Endoscopy, Vol. 51, Núm. 2, pp. 142-151
-
Spanish Results of the Second European Cardiac Resynchronization Therapy Survey (CRT-Survey II)
Revista Espanola de Cardiologia, Vol. 72, Núm. 12, pp. 1020-1030
2018
-
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)
Oncologist, Vol. 23, Núm. 4, pp. 422-432
-
Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study
Arthritis Care and Research, Vol. 70, Núm. 4, pp. 582-591
2017
-
Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection
Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237
2016
-
Colorectal cancer risk factors in patients with serrated polyposis syndrome: A large multicentre study
Gut, Vol. 65, Núm. 11, pp. 1829-1837
-
First month prednisone dose predicts prednisone burden during the following 11 months: An observational study from the RELES cohort
Lupus Science and Medicine, Vol. 3, Núm. 1
-
Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus
Clinical and Experimental Rheumatology, Vol. 34, Núm. 3, pp. 466-472
2015
-
Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis
World Journal of Gastroenterology, Vol. 21, Núm. 30, pp. 9163-9174
2014
-
Registry of the Spanish network of Behçet's disease: A descriptive analysis of 496 patients
Clinical and Experimental Rheumatology, Vol. 32, pp. S33-S39
2013
-
Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide
Annals of Hematology, Vol. 92, Núm. 6, pp. 771-775
2011
-
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation
Blood, Vol. 118, Núm. 3, pp. 529-534
2008
-
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092
2003
-
Autologous stem cell transplantation for primary refractory Hodgkin's disease: Results and clinical variables affecting outcome
Annals of Oncology, Vol. 14, Núm. 5, pp. 745-751